(Total Views: 216)
Posted On: 06/05/2023 4:14:23 PM
Post# of 707
NetworkNewsBreaks – IGC Pharma Inc.’s (NYSE American: IGC) Advisor and Inventor of TGR-63 Receives National Technology Award
IGC Pharma (NYSE American: IGC) today announced recognition of its advisor, Professor T. Govindaraju, the inventor of the investigational Alzheimer’s drug candidate, TGR-63. According to the announcement, Govindaraju received the Government of India-instituted National Technology Award (Translational Research) for “Outstanding Contribution in Commercializing Innovative Indigenous Technologies” from the Minister of State for Science and Technology and Earth Sciences. The Department of Science and Technology (“DST”)-Technology Development Board (“TDB”), Government of India presented Professor Govindaraju with the prestigious award on May 14, 2023. The awards acknowledge excellence and success in the commercialization of technology indigenous to India, and Professor Govindaraju is celebrated for his innovative approach to developing therapeutics.
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
IGC Pharma (NYSE American: IGC) today announced recognition of its advisor, Professor T. Govindaraju, the inventor of the investigational Alzheimer’s drug candidate, TGR-63. According to the announcement, Govindaraju received the Government of India-instituted National Technology Award (Translational Research) for “Outstanding Contribution in Commercializing Innovative Indigenous Technologies” from the Minister of State for Science and Technology and Earth Sciences. The Department of Science and Technology (“DST”)-Technology Development Board (“TDB”), Government of India presented Professor Govindaraju with the prestigious award on May 14, 2023. The awards acknowledge excellence and success in the commercialization of technology indigenous to India, and Professor Govindaraju is celebrated for his innovative approach to developing therapeutics.
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)
